472 Anti-VEGF treatment amplifies immune checkpoint inhibitor induced immune responses by targeting...
472 Anti-VEGF treatment amplifies immune checkpoint inhibitor induced immune responses by targeting B and regulatory T cells
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundWe have previously reported early and unexpected results of an open label phase II trial treating patients with histologically confirmed hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) treated with anti-CTLA4 + anti-VEGF + anti-PD-L1. We described exceptional clinical responses in 6 out of 7 patients accompanied with moderate...
Alternative Titles
Full title
472 Anti-VEGF treatment amplifies immune checkpoint inhibitor induced immune responses by targeting B and regulatory T cells
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_36166d818bed4c0ea8f1b8a8241f0a7a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_36166d818bed4c0ea8f1b8a8241f0a7a
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2023-SITC2023.0472
